Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01273766 · ClinicalTrials.gov registry record · Phase 2
Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies
A Phase 2 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT01273766 is a Phase 2 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 16 participants.
The verdict
NCT01273766, a Phase 2 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
RATIONALE: Deferasirox may remove excess iron from the body caused by blood transfusions. PURPOSE: This clinical trial studies deferasirox in treating iron overload caused by blood transfusions in patients with hematologic malignancies.
Interventions
- OTHER laboratory biomarker analysis
- OTHER enzyme-linked immunosorbent assay
- DRUG deferasirox
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2011-01 |
| Est. Completion | 2014-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01273766
The ClinicalTrials.gov registry entry for NCT01273766 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT01273766 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01273766 about?
NCT01273766 is a clinical study titled "Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies". RATIONALE: Deferasirox may remove excess iron from the body caused by blood transfusions. PURPOSE: This clinical trial studies deferasirox in treating iron overload caused by blood transfusions in patients with hematologic malignancies.
What is the current status of trial NCT01273766?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2011-01. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01273766?
The interventions under investigation include: laboratory biomarker analysis (OTHER), enzyme-linked immunosorbent assay (OTHER), deferasirox (DRUG).
Who is sponsoring clinical trial NCT01273766?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.